Ad
related to: is aficamten fda approved medication for cardiomyopathy- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
- Genetic Testing
for patients and their families at
risk of a genetic heart condition
- What is Cardiomyopathy
Types, causes & symptoms
Diagnosing & treating
- Should I See A Heart Doc
Talk to your doc about your heart
and learn what to ask
- Prepare For Your Visit
What to bring to your visit
plus heart & vascular resources
- Genetic Testing
Search results
Results from the WOW.Com Content Network
Aficamten (CK-274) is a cardiac myosin inhibitor [1] developed by Cytokinetics for the treatment of obstructive hypertrophic cardiomyopathy. [2] [3] [4] References
MYK-224 is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy. [1] [2] [3] References
Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic obstructive HCM from the U.S. Food & Drug Administration (FDA) as well as the National Medical Products Administration (NMPA) in China. Cytokinetics submitted a New Drug Application (NDA) to the FDA in Q3 2024 and expects to submit a Marketing Authorization ...
The presentations included an integrated safety analysis from three clinical studies of aficamten and an analysis of the withdrawal of standard of care medications in patients treated with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical study of ...
Acoramidis, sold under the brand name Attruby, is a medication used for the treatment of cardiomyopathy. [1] It is a near-complete (>90%) transthyretin stabilizer, developed to mimic the protective properties of the naturally-occurring T119M mutation, [2] [3] to treat transthyretin amyloid cardiomyopathy. It is taken by mouth. [1]
This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Details of the deal, including its price, were not disclosed. Start Your Mornings Smarter!
The regulator, in its so-called complete response letter, said the drug patisiran did not meaningfully improve the condition of patients with heart muscle issues or cardiomyopathy caused by ATTR ...
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions. [9]
Ad
related to: is aficamten fda approved medication for cardiomyopathy- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
